Vaccines and Neurologic Disease

ABSTRACT

Vaccines have undoubtedly been a medical milestone, preventing immeasurable morbidity and mortality from infectious diseases worldwide. Modern vaccines have tremendously reduced the global impact of numerous infections; they have succeeded in eliminating smallpox completely. However, the nature by which vaccines confer their protection—by stimulation of the immune system—means that in rare cases, adverse often immunologically mediated events may occur following vaccination. Some of the most severe of these involve the nervous system. The author provides an overview of the mechanisms of vaccinology, and describes the various vaccines available for particular neurologic illnesses. Possible neurologic adverse events following vaccinations, and the possible mechanisms of these events, are also discussed. Finally, procedures in place to ensure vaccine safety are reviewed.

KEYWORDS

Vaccines - encephalitis - virus - adverse events

REFERENCES

• 1 Centers for Disease Control and Prevention (CDC) . Ten great public health achievements—United States, 1900-1999.  MMWR Morb Mortal Wkly Rep. 1999;  48 (12) 241-243
• 2 World Health Organization .The Global Eradication of Smallpox: Final Report of the Global Commission for the Certification of Smallpox Eradication. Geneva: World Health Organization; 1980
• 3 Riedel S. Edward Jenner and the history of smallpox and vaccination.  Proc (Bayl Univ Med Cent). 2005;  18 (1) 21-25 (Bayl Univ Med Cent)
• 4 Plotkin S A, Orenstein W, Offit P A Eds.. Vaccines. 5th ed. Philadelphia: Saunders; 2008
• 5 Centers for Disease Control and Prevention . Recommended immunization schedules for persons aged 0–18 years—United States, 2011.  MMWR Morb Mortal Wkly Rep. 2011;  60 (5) 1-4
• 6 Advisory Committee for Immunization Practices .ACIP Vaccine Recommendations. Atlanta, GA: Centers for Disease Control and Prevention; 2011
• 7 WHO Expert Committee on Biological Standardization. Recommendations for inactivated rabies vaccine for human use produced in cell substrates and embryonated eggs. Geneva: World Health Organization; 2005
• 8 World Health Organization . Cholera vaccines: WHO position paper.  Wkly Epidemiol Rec. 2010;  85 (13) 117-128
• 9 Centers for Disease Control and Prevention. Typhoid immunization.  MMWR Recomm Rep. 1994;  43 (RR-14)
• 10 Centers for Disease Control and Prevention .Travelers' Health, Vaccination. Atlanta, GA: Centers for Disease Control and Prevention; 2009
• 11 Paessler S, Weaver S C. Vaccines for Venezuelan equine encephalitis.  Vaccine. 2009;  27 (Suppl 4) D80-D85
• 12 Centers for Disease Control and Prevention. Advisory Committee for Immunization Practices. Updated Tdap Vaccine Recommendations from the ACIP, 2010. Atlanta, GA: Centers for Disease Control and Prevention; 2010
• 13 Mandell G L, Bennett J E, Dolin R. Principles and Practice of Infectious Disease. 6th ed. Philadelphia: Elsevier Churchill Livingstone; 2005
• 14 Dalakas M C, Sever J L, Madden D L et al.. Late postpoliomyelitis muscular atrophy: clinical, virologic, and immunologic studies.  Rev Infect Dis. 1984;  6 (Suppl 2) S562-S567
• 15 Dalakas M C, Bartfeld H, Kurland L T. The postpolio syndrome: advances in the pathogenesis and treatment.  Ann N Y Acad Sci. 1995;  753 1-412
• 16 Nathanson N, Kew O M. From emergence to eradication: the epidemiology of poliomyelitis deconstructed.  Am J Epidemiol. 2010;  172 (11) 1213-1229
• 17 Centers for Disease Control and Prevention (CDC) . Certification of poliomyelitis eradication—the Americas, 1994.  MMWR Morb Mortal Wkly Rep. 1994;  43 (39) 720-722
• 18 Centers for Disease Control and Prevention (CDC) . Progress toward interruption of wild poliovirus transmission - worldwide, 2009.  MMWR Morb Mortal Wkly Rep. 2010;  59 (18) 545-550
• 19 Esteves K. Safety of oral poliomyelitis vaccine: results of a WHO enquiry.  Bull World Health Organ. 1988;  66 (6) 739-746
• 20 Prevots D R, Sutter R W, Strebel P M, Weibel R E, Cochi S L. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Implications for estimating the risk of vaccine-associated disease.  Arch Pediatr Adolesc Med. 1994;  148 (5) 479-485
• 21 Wunner W H, Briggs D J. Rabies in the 21 century.  PLoS Negl Trop Dis. 2010;  4 (3) e591
• 22 Briggs D J. World Rabies Day: working together to make rabies history.  Vaccine. 2007;  25 6830-6831
• 23 Dodet B. Asian Rabies Expert Bureau (AREB) . An important date in rabies history.  Vaccine. 2007;  25 (52) 8647-8650
• 24 Culbertson C G, Peck Jr F B, Powell H M. Duck-embryo rabies vaccine; study of fixed virus vaccine grown in embryonated duck eggs and killed with beta-propiolactone (BPL).  J Am Med Assoc. 1956;  162 (15) 1373-1376
• 25 Fuenzalida E, Palacios R, Borgono J M. Antirabies antibody response in man to vaccine made from infected suckling-mouse brains.  Bull World Health Organ. 1964;  30 431-436
• 26 World Health Organization . Rabies vaccines. WHO position paper.  Wkly Epidemiol Rec. 2007;  82 (49-50) 425-435
• 27 Gubler D J. The global emergence/resurgence of arboviral diseases as public health problems.  Arch Med Res. 2002;  33 (4) 330-342
• 28 Wang S P. Japanese encephalitis in Taiwan: a review of recent studies.  Bull World Health Organ. 1964;  30 279-284
• 29 Parida M, Dash P K, Tripathi N K et al.. Japanese Encephalitis Outbreak, India, 2005.  Emerg Infect Dis. 2006;  12 (9) 1427-1430
• 30 Richter R W, Shimojyo S. Neurologic sequelae of Japanese B encephalitis.  Neurology. 1961;  11 553-559
• 31 Grossberg S, Heyman A, Keehn R J. Neurologic sequelae of Japanese encephalitis. Report of a cooperative study.  Trans Am Neurol Assoc. 1962;  87 114-117
• 32 Huy B V, Tu H C, Luan T V, Lindqvist R. Early mental and neurological sequelae after Japanese B encephalitis.  Southeast Asian J Trop Med Public Health. 1994;  25 (3) 549-553
• 33 Baruah H C, Biswas D, Patgiri D, Mahanta J. Clinical outcome and neurological sequelae in serologically confirmed cases of Japanese encephalitis patients in Assam, India.  Indian Pediatr. 2002;  39 (12) 1143-1148
• 34 Kuttner A G, Ts'un T. Encephalitis in north China. Results obtained with neutralization tests.  J Clin Invest. 1936;  15 (5) 525-530
• 35 Wilder-Smith A, Halstead S B. Japanese encephalitis: update on vaccines and vaccine recommendations.  Curr Opin Infect Dis. 2010;  23 (5) 426-431
• 36 Centers for Disease Control and Prevention . Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 1993;  42 (RR-1) 1-15
• 37 Guess H A, Broughton D D, Melton III L J, Kurland L T. Population-based studies of varicella complications.  Pediatrics. 1986;  78 (4 Pt 2) 723-727
• 38 Preblud S R. Varicella: complications and costs.  Pediatrics. 1986;  78 (4 Pt 2) 728-735
• 39 Choo P W, Donahue J G, Manson J E, Platt R. The epidemiology of varicella and its complications.  J Infect Dis. 1995;  172 (3) 706-712
• 40 Mueller N H, Gilden D H, Cohrs R J, Mahalingam R, Nagel M A. Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency.  Neurol Clin. 2008;  26 (3) 675-697 viii viii
• 41 Marin M, Güris D, Chaves S S, Schmid S, Seward J F. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC) . Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 2007;  56 (RR-4, RR-04) 1-40
• 42 Marin M, Broder K R, Temte J L, Snider D E, Seward J F. Centers for Disease Control and Prevention (CDC) . Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 2010;  59 (RR-3) 1-12
• 43 Plotkin S A, Starr S E, Connor K, Morton D. Zoster in normal children after varicella vaccine.  J Infect Dis. 1989;  159 (5) 1000-1001
• 44 White C J. Clinical trials of varicella vaccine in healthy children.  Infect Dis Clin North Am. 1996;  10 (3) 595-608
• 45 Harpaz R, Ortega-Sanchez I R, Seward J F. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC) . Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 2008;  57 (RR-5) 1-30 quiz CE2-CE4
• 46 Oxman M N. Zoster vaccine: current status and future prospects.  Clin Infect Dis. 2010;  51 (2) 197-213
• 47 Sanford M, Keating G M. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults.  Drugs Aging. 2010;  27 (2) 159-176
• 48 Advisory Committee on Immunization Practices . Recommended adult immunization schedule: United States, 2011.  Ann Intern Med. 2011;  154 (3) 168-173
• 49 Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.  Ann Intern Med. 2006;  145 (5) 317-325
• 50 Pellissier J M, Brisson M, Levin M J. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.  Vaccine. 2007;  25 (49) 8326-8337
• 51 Rothberg M B, Virapongse A, Smith K J. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.  Clin Infect Dis. 2007;  44 (10) 1280-1288
• 52 Rosenstein N E, Perkins B A, Stephens D S, Popovic T, Hughes J M. Meningococcal disease.  N Engl J Med. 2001;  344 (18) 1378-1388
• 53 Molesworth A M, Thomson M C, Connor S J et al.. Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa.  Trans R Soc Trop Med Hyg. 2002;  96 (3) 242-249
• 54 Khatami A, Pollard A J. The epidemiology of meningococcal disease and the impact of vaccines.  Expert Rev Vaccines. 2010;  9 (3) 285-298
• 55 Rosenstein N E, Perkins B A. Update on Haemophilus influenzae serotype b and meningococcal vaccines.  Pediatr Clin North Am. 2000;  47 (2) 337-352, vi vi
• 56 Cartwright K, Noah N, Peltola H. Meningococcal Disease Advisory Board . Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6-8 October, 2000.  Vaccine. 2001;  19 (31) 4347-4356
• 57 Rosenstein N E, Perkins B A, Stephens D S et al.. The changing epidemiology of meningococcal disease in the United States, 1992-1996.  J Infect Dis. 1999;  180 (6) 1894-1901
• 58 Pollard A J, Levin M. Vaccines for prevention of meningococcal disease.  Pediatr Infect Dis J. 2000;  19 (4) 333-344, quiz 345
• 59 Pollard A J, Maiden M C. Epidemic meningococcal disease in sub-Saharan Africa—towards a sustainable solution?.  Lancet Infect Dis. 2003;  3 (2) 68-70
• 60 Pollard A J. Global epidemiology of meningococcal disease and vaccine efficacy.  Pediatr Infect Dis J. 2004;  23 (12, Suppl) S274-S279
• 61 Centers for Disease Control and Prevention (CDC) . Updated recommendations for use of meningococcal conjugate vaccines — Advisory Committee on Immunization Practices (ACIP), 2010.  MMWR Morb Mortal Wkly Rep. 2011;  60 (3) 72-76
• 62 World Health Organization . Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines.  Wkly Epidemiol Rec. 2002;  77 (40) 331-339
• 63 Brook I. Current concepts in the management of Clostridium tetani infection.  Expert Rev Anti Infect Ther. 2008;  6 (3) 327-336
• 64 Pascual F B, McGinley E L, Zanardi L R, Cortese M M, Murphy T V. Tetanus surveillance—United States, 1998–2000.  MMWR Surveill Summ. 2003;  52 (3) 1-8
• 65 Galazka A, Bermingham M, Kurian M, Gasse F. Tetanus. In: Murray C JL, Lopez A D, Mathers C D, eds. The Global Epidemiology of Infectious Diseases. Geneva: World Health Organization; 2004: 151-199
• 66 Gardner P. Issues related to the decennial tetanus-diphtheria toxoid booster recommendations in adults.  Infect Dis Clin North Am. 2001;  15 (1) 143-153
• 67 Centers for Disease Control and Prevention (CDC) . Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010.  MMWR Morb Mortal Wkly Rep. 2011;  60 (1) 13-15
• 68 Kretsinger K, Broder K R, Cortese M M Centers for Disease Control and Prevention et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel.  MMWR Recomm Rep. 2006;  55 (RR-17) 1-37
• 69 Roper M H, Vandelaer J H, Gasse F L. Maternal and neonatal tetanus.  Lancet. 2007;  370 (9603) 1947-1959
• 70 Garren H. A DNA vaccine for multiple sclerosis.  Expert Opin Biol Ther. 2008;  8 (10) 1539-1550
• 71 Hickey M J, Malone C C, Erickson K L et al.. Cellular and vaccine therapeutic approaches for gliomas.  J Transl Med. 2010;  8 100
• 72 A vaccine against meningitis in Africa.  Lancet Infect Dis. 2011;  11 (1) 1
• 73 Biedenbender R, Bevilacqua J, Gregg A M, Watson M, Dayan G. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults.  J Infect Dis. 2011;  203 (1) 75-84
• 74 Smith L A. Botulism and vaccines for its prevention.  Vaccine. 2009;  27 (Suppl 4) D33-D39
• 75 Rivers TMSF, Schwentker F F. Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys.  J Exp Med. 1935;  61 (5) 689-702
• 76 Vital C, Vital A, Gbikpi-Benissan G et al.. Postvaccinal inflammatory neuropathy: peripheral nerve biopsy in 3 cases.  J Peripher Nerv Syst. 2002;  7 (3) 163-167
• 77 Levin M C, Krichavsky M, Berk J et al.. Neuronal molecular mimicry in immune-mediated neurologic disease.  Ann Neurol. 1998;  44 (1) 87-98
• 78 Kalume F, Lee S M, Morcos Y, Callaway J C, Levin M C. Molecular mimicry: cross-reactive antibodies from patients with immune-mediated neurologic disease inhibit neuronal firing.  J Neurosci Res. 2004;  77 (1) 82-89
• 79 Pou M A, Diaz-Torne C, Vidal S et al.. Development of autoimmune diseases after vaccination.  J Clin Rheumatol. 2008;  14 (4) 243-244
• 80 Orbach H, Agmon-Levin N, Zandman-Goddard G. Vaccines and autoimmune diseases of the adult.  Discov Med. 2010;  9 (45) 90-97
• 81 Johnson R Ed.. Postinfectious Demyelinating Disease. Philadelphia, New York: Lippincott-Raven; 1998: 181-211
• 82 Fenichel G M. Neurological complications of immunization.  Ann Neurol. 1982;  12 (2) 119-128
• 83 Miravalle A, Biller J, Schnitzler E, Bonwit A. Neurological complications following vaccinations.  Neurol Res. 2010;  32 (3) 285-292
• 84 Piyasirisilp S, Schmeckpeper B J, Chandanayingyong D, Hemachudha T, Griffin D E. Association of HLA and T-cell receptor gene polymorphisms with Semple rabies vaccine-induced autoimmune encephalomyelitis.  Ann Neurol. 1999;  45 (5) 595-600
• 85 Hemachudha T, Phanuphak P, Johnson R T, Griffin D E, Ratanavongsiri J, Siriprasomsup W. Neurologic complications of Semple-type rabies vaccine: clinical and immunologic studies.  Neurology. 1987;  37 (4) 550-556
• 86 Hemachudha T, Griffin D E, Giffels J J, Johnson R T, Moser A B, Phanuphak P. Myelin basic protein as an encephalitogen in encephalomyelitis and polyneuritis following rabies vaccination.  N Engl J Med. 1987;  316 (7) 369-374
• 87 Hemachudha T, Griffin D E, Chen W W, Johnson R T. Immunologic studies of rabies vaccination-induced Guillain-Barré syndrome.  Neurology. 1988;  38 (3) 375-378
• 88 Takahashi H, Pool V, Tsai T F, Chen R T. The VAERS Working Group . Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States.  Vaccine. 2000;  18 (26) 2963-2969
• 89 Swicowa K, Mostowiec S. [Neurological complications following smallpox vaccination].  Pediatr Pol. 1964;  39 1207-1211
• 90 Siegert R. [Behaviour of vaccinia virus in central nervous system injury caused by vaccine. II. Virological studies in the central nervous system].  Dtsch Med Wochenschr. 1957;  82 (49) 2061-2065
• 91 Siegert R. [Behaviour of vaccinia virus in central nervous injury caused by vaccine. I. Virological studies at the inoculation site, in the regional lymph nodes and in the blood].  Dtsch Med Wochenschr. 1957;  82 (48) 2021-2024
• 92 Fatal viral encephalitis following 17D yellow fever vaccine inoculation. Report of a case in a 3-year-old child.  JAMA. 1966;  198 (6) 671-672
• 93 McMahon A W, Eidex R B, Marfin A A Yellow Fever Working Group et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases.  Vaccine. 2007;  25 (10) 1727-1734
• 94 Lista F, Faggioni G, Peragallo M S et al.. Molecular analysis of early postvaccine mumps-like disease in Italian military recruits.  JAMA. 2002;  287 (9) 1114-1115
• 95 Neustadt R E, Fineberg H V. The Swine Flu Affair. Honolulu: University Press of the Pacific; 2005
• 96 Schonberger L B, Bregman D J, Sullivan-Bolyai J Z et al.. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977.  Am J Epidemiol. 1979;  110 (2) 105-123
• 97 Breman J G, Hayner N S. Guillain-Barré syndrome and its relationship to swine influenza vaccination in Michigan, 1976-1977.  Am J Epidemiol. 1984;  119 (6) 880-889
• 98 Langmuir A D, Bregman D J, Kurland L T, Nathanson N, Victor M. An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines.  Am J Epidemiol. 1984;  119 (6) 841-879
• 99 Safranek T J, Lawrence D N, Kurland L T Expert Neurology Group et al. Reassessment of the association between Guillain-Barré syndrome and receipt of swine influenza vaccine in 1976-1977: results of a two-state study.  Am J Epidemiol. 1991;  133 (9) 940-951
• 100 Hurwitz E S, Schonberger L B, Nelson D B, Holman R C. Guillain-Barré syndrome and the 1978-1979 influenza vaccine.  N Engl J Med. 1981;  304 (26) 1557-1561
• 101 Kaplan J E, Katona P, Hurwitz E S, Schonberger L B. Guillain-Barré syndrome in the United States, 1979-1980 and 1980-1981. Lack of an association with influenza vaccination.  JAMA. 1982;  248 (6) 698-700
• 102 Kaplan J E, Schonberger L B, Hurwitz E S, Katona P. Guillain-Barré syndrome in the United States, 1978-1981: additional observations from the national surveillance system.  Neurology. 1983;  33 (5) 633-637
• 103 Roscelli J D, Bass J W, Pang L. Guillain-Barré syndrome and influenza vaccination in the US Army, 1980-1988.  Am J Epidemiol. 1991;  133 (9) 952-955
• 104 Chen R T, Kent J, Rhodes P, Simon P, Schonberger L. Investigation of a possible association between influenza vaccination and Guillain-Barre syndrome in the United States, 1990–1991.  Post Mark Surveill. 1992;  6 (1) 5-6
• 105 Lasky T, Terracciano G J, Magder L et al.. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines.  N Engl J Med. 1998;  339 (25) 1797-1802
• 106 Haber P, DeStefano F, Angulo F J et al.. Guillain-Barré syndrome following influenza vaccination.  JAMA. 2004;  292 (20) 2478-2481
• 107 Juurlink D N, Stukel T A, Kwong J et al.. Guillain-Barré syndrome after influenza vaccination in adults: a population-based study.  Arch Intern Med. 2006;  166 (20) 2217-2221
• 108 Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database.  Am J Epidemiol. 2009;  169 (3) 382-388
• 109 Nachamkin I, Shadomy S V, Moran A P et al.. Anti-ganglioside antibody induction by swine (A/NJ/1976/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain-Barré syndrome.  J Infect Dis. 2008;  198 (2) 226-233
• 110 Lopez Adaros H, Held J R. Guillain-Barré syndrome associated with immunization against rabies: epidemiological aspects.  Res Publ Assoc Res Nerv Ment Dis. 1971;  49 178-186
• 111 Pollard J D, Selby G. Relapsing neuropathy due to tetanus toxoid. Report of a case.  J Neurol Sci. 1978;  37 (1-2) 113-125
• 112 Tuttle J, Chen R T, Rantala H, Cherry J D, Rhodes P H, Hadler S. The risk of Guillain-Barré syndrome after tetanus-toxoid-containing vaccines in adults and children in the United States.  Am J Public Health. 1997;  87 (12) 2045-2048
• 113 Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain-Barré syndrome.  Drug Saf. 2009;  32 (4) 309-323
• 114 Stratton K, Almario D A, McCormick M C. Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders. Washington, DC: Institute of Medicine; 2002
• 115 Ascherio A, Zhang S M, Hernán M A et al.. Hepatitis B vaccination and the risk of multiple sclerosis.  N Engl J Med. 2001;  344 (5) 327-332
• 116 Confavreux C, Suissa S, Saddier P, Bourdès V, Vukusic S. Vaccines in Multiple Sclerosis Study Group . Vaccinations and the risk of relapse in multiple sclerosis.  N Engl J Med. 2001;  344 (5) 319-326
• 117 DeStefano F, Verstraeten T, Chen R T. Hepatitis B vaccine and risk of multiple sclerosis.  Expert Rev Vaccines. 2002;  1 (4) 461-466
• 118 Harris C, Lee K. Acute disseminated encephalomyelitis.  J Neurosci Nurs. 2007;  39 (4) 208-212
• 119 Wingerchuk D M. Acute disseminated encephalomyelitis: distinction from multiple sclerosis and treatment issues.  Adv Neurol. 2006;  98 303-318
• 120 Young N P, Weinshenker B G, Lucchinetti C F. Acute disseminated encephalomyelitis: current understanding and controversies.  Semin Neurol. 2008;  28 (1) 84-94
• 121 Tenembaum S N. Disseminated encephalomyelitis in children.  Clin Neurol Neurosurg. 2008;  110 (9) 928-938
• 122 Murthy S N, Faden H S, Cohen M E, Bakshi R. Acute disseminated encephalomyelitis in children.  Pediatrics. 2002;  110 (2 Pt 1) e21
• 123 Mihai C, Jubelt B. Post-infectious encephalomyelitis.  Curr Neurol Neurosci Rep. 2005;  5 (6) 440-445
• 124 Murphy J, Austin J. Spontaneous infection or vaccination as cause of acute disseminated encephalomyelitis.  Neuroepidemiology. 1985;  4 (3) 138-145
• 125 Solomon T. New vaccines for Japanese encephalitis.  Lancet Neurol. 2008;  7 (2) 116-118
• 126 Moore Z S, Seward J F, Lane J M. Smallpox.  Lancet. 2006;  367 (9508) 425-435
• 127 Lane J M, Ruben F L, Neff J M, Millar J D. Complications of smallpox vaccination, 1968.  N Engl J Med. 1969;  281 (22) 1201-1208
• 128 De Vries E. Post Vaccinial Perivenous Encephalitis. Amsterdam: Elsevier; 1960
• 129 Miller D L, Ross E M, Alderslade R, Bellman M H, Rawson N S. Pertussis immunisation and serious acute neurological illness in children.  Br Med J (Clin Res Ed). 1981;  282 (6276) 1595-1599
• 130 Miller D C, Wadsworth M J, Ross E M. Pertussis vaccine and severe acute neurological illnesses. Response to a recent review by members of the NCES team.  Vaccine. 1989;  7 (6) 487-489
• 131 Safety of pertussis vaccine.  Lancet. 1990;  335 (8690) 655-656
• 132 Griffin M R, Ray W A, Mortimer E A, Fenichel G M, Schaffner W. Risk of seizures and encephalopathy after immunization with the diphtheria-tetanus-pertussis vaccine.  JAMA. 1990;  263 (12) 1641-1645
• 133 Stratton K R, How C J, Johnston R B. DPT Vaccine and Chronic Nervous System Dysfunction: A New Analysis. Washington, DC: National Academy Press; 1994
• 134 Currenti S A. Understanding and determining the etiology of autism.  Cell Mol Neurobiol. 2010;  30 (2) 161-171
• 135 Wakefield A J, Murch S H, Anthony A et al.. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children.  Lancet. 1998;  351 (9103) 637-641
• 136 Farrington C P, Miller E, Taylor B. MMR and autism: further evidence against a causal association.  Vaccine. 2001;  19 (27) 3632-3635
• 137 Smeeth L, Hall A J, Fombonne E, Rodrigues L C, Huang X, Smith P G. A case-control study of autism and mumps-measles-rubella vaccination using the general practice research database: design and methodology.  BMC Public Health. 2001;  1 2
• 138 Hornig M, Briese T, Buie T et al.. Lack of association between measles virus vaccine and autism with enteropathy: a case-control study.  PLoS ONE. 2008;  3 (9) e3140
• 139 Bedford H E, Elliman D A. MMR vaccine and autism.  BMJ. 2010;  340 c655
• 140 Retraction—Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children.  Lancet. 2010;  375 (9713) 445
• 141 American Academy of Pediatrics. Committee on Infectious Diseases and Committee on Environmental Health . Thimerosal in vaccines—An interim report to clinicians.  Pediatrics. 1999;  104 (3 Pt 1) 570-574
• 142 Madsen K M, Lauritsen M B, Pedersen C B et al.. Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data.  Pediatrics. 2003;  112 (3 Pt 1) 604-606
• 143 Stehr-Green P, Tull P, Stellfeld M, Mortenson P B, Simpson D. Autism and thimerosal-containing vaccines: lack of consistent evidence for an association.  Am J Prev Med. 2003;  25 (2) 101-106
• 144 Stratton K, Gable A, McCormick M C. Immunization Safety Review: Thimerosal-containing vaccines and neurodevelopmental disorders. Washington, DC: National Academy Press; 2001
• 145 Pritchard J, Mukherjee R, Hughes R A. Risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation.  J Neurol Neurosurg Psychiatry. 2002;  73 (3) 348-349
• 146 Kuitwaard K, van Koningsveld R, Ruts L, Jacobs B C, van Doorn P A. Recurrent Guillain-Barré syndrome.  J Neurol Neurosurg Psychiatry. 2009;  80 (1) 56-59
• 147 Rutschmann O T, McCrory D C, Matchar D B. Immunization Panel of the Multiple Sclerosis Council for Clinical Practice Guidelines . Immunization and MS: a summary of published evidence and recommendations.  Neurology. 2002;  59 (12) 1837-1843
• 148 Fiore A E, Uyeki T M, Broder K Centers for Disease Control and Prevention (CDC) et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.  MMWR Recomm Rep. 2010;  59 (RR-8) 1-62
• 149 Broder K R, Cortese M M, Iskander J K Advisory Committee on Immunization Practices (ACIP) et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 2006;  55 (RR-3) 1-34
• 150 Chen R T, Rastogi S C, Mullen J R et al.. The vaccine adverse event reporting system (VAERS).  Vaccine. 1994;  12 (6) 542-550
• 151 Singleton J A, Lloyd J C, Mootrey G T, Salive M E, Chen R T. VAERS Working Group . An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system.  Vaccine. 1999;  17 (22) 2908-2917
• 152 Chen R T, Glasser J W, Rhodes P H The Vaccine Safety Datalink Team et al. Vaccine safety datalink project: a new tool for improving vaccine safety monitoring in the United States.  Pediatrics. 1997;  99 (6) 765-773
• 153 Greene S K, Kulldorff M, Lewis E M et al.. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project.  Am J Epidemiol. 2010;  171 (2) 177-188
• 154 Perkins F T. Safety of vaccines.  Br Med Bull. 1969;  25 (2) 208-212
• 155 Bohlke K, Davis R L, Marcy S M Vaccine Safety Datalink Team et al. Risk of anaphylaxis after vaccination of children and adolescents.  Pediatrics. 2003;  112 (4) 815-820
• 156 Fisher M C. Vaccine safety.  Pediatr Infect Dis J. 2008;  27 (9) 827-830
• 157 Demirjian A, Levy O. Safety and efficacy of neonatal vaccination.  Eur J Immunol. 2009;  39 (1) 36-46
• 158 Lopalco P L, Johansen K, Ciancio B, De Carvalho Gomes H, Kramarz P, Giesecke J. Monitoring and assessing vaccine safety: a European perspective.  Expert Rev Vaccines. 2010;  9 (4) 371-380